Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
191 hedge funds and large institutions have $369M invested in Verve Therapeutics in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 55 increasing their positions, 64 reducing their positions, and 16 closing their positions.
213% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $348K
156% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 16
15% more funds holding
Funds holding: 166 → 191 (+25)
1.96% less ownership
Funds ownership: 92.92% → 90.95% (-2%)
14% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 64
17% less capital invested
Capital invested by funds: $444M → $369M (-$74.6M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$18.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$7.27M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$6.11M |
| 4 |
Goldman Sachs
New York
|
+$4.5M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$4.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$12.1M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$8.01M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$5.8M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$3.64M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.97M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCM
201
Teza Capital Management
Chicago,
Illinois
| – | -$64.7K | -11,468 | Closed |
|
|
VEA
202
Virtus ETF Advisers
New York
| – | -$64.4K | -11,411 | Closed |
|
|
BIG
203
Brooklyn Investment Group
Brooklyn,
New York
| – | -$10.2K | -1,810 | Closed |
|
|
CAM
204
Creekmur Asset Management
Morton,
Illinois
| – | -$107 | -19 | Closed |
|
205
Bessemer Group
Woodbridge,
New Jersey
| – | +$322 | +48 | New |
|
VERV Hedge Fund Activity: Q1 2025 in Review
191 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q1 2025, worth a combined $369M — down 17% from $444M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new VERV positions and 16 closed out — a net gain of 25 holders — while 55 added to existing stakes and 64 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $18.5M. The largest seller was Millennium Management, cutting an estimated $12.1M.
- 191 institutional investors held Verve Therapeutics (VERV) as of Q1 2025, up from 166 in Q4 2024.
- Funds reported $369M of Verve Therapeutics stock for Q1 2025, down 17% quarter-over-quarter.
- 41 funds opened new Verve Therapeutics positions in Q1 2025 and 16 closed out, a net change of +25 holders.
- The largest Verve Therapeutics buyer in Q1 2025 was Woodline Partners, an estimated $18.5M added.
- The largest Verve Therapeutics seller in Q1 2025 was Millennium Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q1 2025.